Company logo

BMRN - BioMarin Pharmaceutical Inc.

NASDAQ -> Healthcare -> Biotechnology
San Rafael, United States
Type: Equity

BMRN price evolution
BMRN
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Current assets
Cash $972.15 $747 $755.13 $785.41
Short term investments $252.2 $299.58 $318.68 $340.43
Net receivables $691.23 $637.16 $633.7 $572.5
Inventory $1183.62 $1137.98 $1107.18 $1032.16
Total current assets $3259.63 $2985.01 $2956.09 $2955.31
Long term investments $557.08 $620.55 $611.13 $548
Property, plant & equipment $1052.9 $1060.42 $1066.13 $1067.16
Goodwill & intangible assets $461.73 $475.85 $490.9 $498.68
Total noncurrent assets $3807.49 $3887.66 $3885.51 $3802.86
Total investments $809.28 $920.13 $929.82 $888.43
Total assets $7067.12 $6872.67 $6841.6 $6758.16
Current liabilities
Accounts payable $572.5 $593.54 $683.15 $669.83
Deferred revenue
Short long term debt $494.84 $494.36 $493.88 $493.4
Total current liabilities $1067.34 $1087.9 $1177.02 $1163.22
Long term debt $594.12 $593.61 $593.1 $592.59
Total noncurrent liabilities $713.49 $710.96 $713.03 $698.04
Total debt $1088.95 $1087.96 $1086.97 $1085.98
Total liabilities $1780.82 $1798.86 $1890.05 $1861.27
Shareholders' equity
Retained earnings -$425.72 -$532.89 -$621.55 -$641.93
Other shareholder equity $26.8 -$1.05 -$28.79 $6.26
Total shareholder equity $5286.3 $5073.82 $4951.55 $4896.9
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $755.13 $724.53 $587.28 $649.16
Short term investments $318.68 $567.01 $426.6 $416.23
Net receivables $633.7 $461.32 $373.4 $448.35
Inventory $1107.18 $894.08 $776.67 $698.55
Total current assets $2956.09 $2751.46 $2274.39 $2342.22
Long term investments $611.13 $333.83 $507.79 $285.47
Property, plant & equipment $1066.13 $1114.32 $1035.46 $1032.47
Goodwill & intangible assets $490.9 $534.77 $584.85 $613.47
Total noncurrent assets $3885.51 $3623.62 $3728.94 $3505.8
Total investments $929.82 $900.84 $934.39 $701.7
Total assets $6841.6 $6375.07 $6003.32 $5848.02
Current liabilities
Accounts payable $683.15 $231.24 $491.59 $492.55
Deferred revenue
Short long term debt $493.88
Total current liabilities $1177.02 $588.88 $539.82 $492.55
Long term debt $593.1 $1083.2 $1079.08 $1075.14
Total noncurrent liabilities $713.03 $1183.03 $1192.76 $1249.47
Total debt $1086.97 $1083.02 $1079.08 $1075.14
Total liabilities $1890.05 $1771.92 $1732.59 $1742.02
Shareholders' equity
Retained earnings -$621.55 -$789.2 -$925.69 -$861.61
Other shareholder equity -$28.79 -$0.63 $14.43 -$16.14
Total shareholder equity $4951.55 $4603.16 $4270.74 $4106
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Revenue
Total revenue $712.03 $648.83 $646.21 $581.33
Cost of revenue $130.46 $125.18 $135.48 $124.75
Gross Profit $581.57 $523.65 $510.73 $456.58
Operating activities
Research & development $183.79 $204.99 $206.25 $191.31
Selling, general & administrative $263.03 $225.91 $275.02 $223.93
Total operating expenses $461.12 $435.19 $496.51 $430.92
Operating income $120.45 $88.46 $14.22 $25.66
Income from continuing operations
EBIT $135.71 $109.09 $25.43 $45.45
Income tax expense $24.96 $16.89 -$1.05 $1.29
Interest expense $3.57 $3.55 $6.1 $3.78
Net income
Net income $107.17 $88.66 $20.38 $40.38
Income (for common shares) $107.17 $88.66 $20.38 $40.38
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $2419.23 $2096.04 $1846.28 $1860.45
Cost of revenue $514.85 $483.67 $470.51 $524.27
Gross Profit $1904.37 $1612.37 $1375.76 $1336.18
Operating activities
Research & development $746.77 $649.61 $628.79 $628.12
Selling, general & administrative $937.29 $854.01 $759.38 $737.67
Total operating expenses $1746.28 $1462.81 $1458.1 $1372.95
Operating income $158.1 $149.56 -$82.34 -$36.77
Income from continuing operations
EBIT $205.9 $165.55 -$60.01 -$13.01
Income tax expense $20.92 $8.02 -$11.27 -$901.42
Interest expense $17.34 $15.97 $15.34 $29.31
Net income
Net income $167.65 $141.56 -$64.08 $859.1
Income (for common shares) $167.65 $141.56 -$64.08 $859.1
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Net income $107.17 $88.66 $20.38 $40.38
Operating activities
Depreciation $26.46 $27.35 $26.86 $25.68
Business acquisitions & disposals
Stock-based compensation $47.91 $58.25 $54.85 $48.39
Total cash flows from operations $118.76 $46.97 $27.48 $135.65
Investing activities
Capital expenditures -$21.33 -$16.1 -$28.92 -$21.73
Investments $112.32 $9.87 -$28.27 -$22.38
Total cash flows from investing $90.48 -$14.24 -$64.96 -$45.8
Financing activities
Dividends paid
Sale and purchase of stock $29.42 $7.2 $14.8 $4.36
Net borrowings -$0.02 -$0.04 -$0.04 -$0.61
Total cash flows from financing $12.61 -$42.79 $10.84 -$0.79
Effect of exchange rate $3.3 $1.93 -$3.65 $1.97
Change in cash and equivalents $225.15 -$8.13 -$30.29 $91.03
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $167.65 $141.56 -$64.08 $859.1
Operating activities
Depreciation $104.39 $101.97 $108.04 $105.17
Business acquisitions & disposals
Stock-based compensation $207.1 $196.31 $197.26 $189.71
Total cash flows from operations $159.26 $175.9 $304.54 $85.36
Investing activities
Capital expenditures -$96.69 -$17.63 -$95.58 -$47.15
Investments -$3.63 $8.19 -$246.09 $17.46
Total cash flows from investing -$111.24 -$20.03 -$366.31 -$53.62
Financing activities
Dividends paid
Sale and purchase of stock $69.35 $69.33 $49.19 $21.91
Net borrowings -$2.29 -$2.6 -$3.04 $203.84
Total cash flows from financing -$18.73 -$18.65 -$0.05 $181.12
Effect of exchange rate $1.31 $0.03 -$0.06 -$1.15
Change in cash and equivalents $30.6 $137.25 -$61.88 $211.71
Fundamentals
Market cap $13.39B
Enterprise value $13.51B
Shares outstanding 190.36M
Revenue $2.59B
EBITDA $422.04M
EBIT $315.68M
Net Income $256.59M
Revenue Q/Q 19.61%
Revenue Y/Y 15.83%
P/E ratio 52.19
EV/Sales 5.22
EV/EBITDA 32.01
EV/EBIT 42.79
P/S ratio 5.17
P/B ratio 2.55
Book/Share 27.63
Cash/Share 5.11
EPS $1.35
ROA 3.73%
ROE 5.08%
Debt/Equity 0.38
Net debt/EBITDA 1.92
Current ratio 3.05
Quick ratio 1.95